Hepatopulmonary syndrome: An update |
| |
Authors: | Kejal D Gandhi Pahnwat Tonya Taweesedt Munish Sharma Salim Surani |
| |
Affiliation: | Kejal D Gandhi, Department of Internal Medicine, Medstar Washington Hospital Center/Georgetown University, Washigton, DC 20010, United StatesPahnwat Tonya Taweesedt, Munish Sharma, Department of Medicine, Corpus Christi Medical Center, Corpus Christi, TX 78412, United StatesSalim Surani, Department of Medicine, Texas A&M University, Bryan, TX 78413, United StatesSalim Surani, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, United States |
| |
Abstract: | Hepatopulmonary syndrome (HPS) is characterized by defects in oxygenation caused by intra-pulmonary vasodilation occurring because of chronic liver disease, portal hypertension, or congenital portosystemic shunts. Clinical implications of portal hypertension are very well-known, however, awareness of its effect on multiple organs such as the lungs are less known. The presence of HPS in chronic liver disease is associated with increased mortality. Medical therapies available for HPS have not been proven effective and definitive treatment for HPS is mainly liver transplantation (LT). LT improves mortality for patients with HPS drastically. This article provides a review on the definition, clinical presentation, diagnosis, and management of HPS. |
| |
Keywords: | Hepatopulmonary syndrome Chronic liver disease Hypoxemia Intrapulmonary vasodilatation Liver failure |
|
| 点击此处可从《World journal of hepatology》浏览原始摘要信息 |
|